The global Pompe disease treatment market was valued at more than USD721 million in 2015 and is expected to surpass USD1 billion by 2020, says Technavio.
Technavio has announced its latest market research report on Pompe disease treatment for the forecast period, 2016-2020. This market analysis, under the central nervous system vertical, discusses the major drivers and key emerging trends that will influence the growth of the global Pompe disease treatment market during the forecast period. Some of the top vendors listed in this industry analysis include Amicus Therapeutics, Audentes Therapeutics, and Sanofi-Genzyme.
In terms of geographical analysis, EMEA is likely to continue its domination over the global market and is expected to reach a revenue of almost USD634 million by 2020.
“At present, gene therapy is a key focus area in the global Pompe disease treatment market. Gene therapy for Pompe disease is aimed at creating a permanent GAA source through the use of adenoviral, adeno associated, or hybrid adenoviral-adeno associated vectors to introduce a correct sequence coding gene for the deficient enzyme into cells. Several vendors, research institutes, and government bodies are currently engaged in the development of gene-based products for various chronic conditions including Pompe disease,” says Barath Palada, a lead analyst at Technavio for central nervous system.
Click here to request a free sample of this report
The new industry research report from Technavio analyzes some of the key drivers and trends responsible for the growth of this market and its sub-segments.
Reimbursement policies for treatment
The costs associated with the treatment of Pompe disease are very high, USD100,000-USD300,000 per individual per annum, making it difficult for individuals to continue with the treatment for a long period. Organizations such as the Canadian Association of Pompe, Acid Maltase Deficiency Association, and International Pompe Association provide financial support to individuals to continue the therapy. Governments of many countries, such as Sweden, the Netherlands, and South Korea, are also taking initiatives to reimburse the cost of drugs for individuals. Such reimbursement policies are expected to encourage more individuals to opt for the treatment during the forecast period.
Designated under ICD-10 code
ICD codes can be used for reimbursement purposes by private and government insurers. LSDs are covered by various codes listed under ICD-10 CM, a diagnostic code that has been effective since October 2015. It is listed under the E74 parent code of ICD-10 CM. ICD codes designated to a disease ensure quality care for affected individuals and provide comprehensive healthcare data, subsequently promoting the development of advanced disease protocols and clinical pathways.
Shorter development timelines
Shorter development timelines are expected to aid the growth of the market for orphan drugs during the forecast period. The clinical trials of orphan drugs are significantly shorter than those of non-orphan drugs owing to the special status. The clinical trials involving orphan diseases involve fewer individuals than those for non-orphan diseases, making the development process much shorter and faster. Furthermore, orphan drugs not only present the benefit of shorter development timelines but also face comparatively fewer regulatory hurdles.
Some of the other prominent vendors identified in this report are EpiVax, Oxyrane, Sangamo BioSciences, and Valerion Therapeutics.
This research report includes an in-depth analysis, market shares, and sizes of the sub-segments and geography. It provides a comprehensive analysis of the key companies, including their market shares, business overview, and key financials. The market study also offers a detailed analysis of key drivers, challenges, and opportunities influencing this market.
A more detailed analysis is available in the Technavio report titled, ‘Global Pompe Disease Treatment Market 2016-2020’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Human Respiratory Syncytial Virus Drugs Market 2016-2020
- Global Alopecia Drugs Market 2016-2020
- Pompe Disease Market in the US 2015-2019
To read more press releases- click here.
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
https://www.technavio.com/
